CN109938354A - 一种用于增强钙吸收的营养组合物及其应用方法 - Google Patents
一种用于增强钙吸收的营养组合物及其应用方法 Download PDFInfo
- Publication number
- CN109938354A CN109938354A CN201811513099.XA CN201811513099A CN109938354A CN 109938354 A CN109938354 A CN 109938354A CN 201811513099 A CN201811513099 A CN 201811513099A CN 109938354 A CN109938354 A CN 109938354A
- Authority
- CN
- China
- Prior art keywords
- calcium
- alimentation composition
- arginine
- bone
- lysine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 59
- 230000003185 calcium uptake Effects 0.000 title claims abstract description 22
- 238000000034 method Methods 0.000 title claims abstract description 11
- 230000002708 enhancing effect Effects 0.000 title claims abstract description 7
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims abstract description 130
- 239000011575 calcium Substances 0.000 claims abstract description 128
- 229910052791 calcium Inorganic materials 0.000 claims abstract description 128
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims abstract description 39
- 239000004472 Lysine Substances 0.000 claims abstract description 23
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims abstract description 18
- 229930064664 L-arginine Natural products 0.000 claims abstract description 17
- 235000014852 L-arginine Nutrition 0.000 claims abstract description 17
- 235000019766 L-Lysine Nutrition 0.000 claims abstract description 15
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims abstract description 14
- 235000005282 vitamin D3 Nutrition 0.000 claims abstract description 11
- 239000011647 vitamin D3 Substances 0.000 claims abstract description 11
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 claims abstract description 11
- 229940021056 vitamin d3 Drugs 0.000 claims abstract description 11
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims abstract description 9
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims abstract description 9
- 229910052802 copper Inorganic materials 0.000 claims abstract description 9
- 239000010949 copper Substances 0.000 claims abstract description 9
- 229910052725 zinc Inorganic materials 0.000 claims abstract description 9
- 239000011701 zinc Substances 0.000 claims abstract description 9
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 22
- 239000002775 capsule Substances 0.000 claims description 14
- 230000037182 bone density Effects 0.000 claims description 12
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 11
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 claims description 8
- 229910052748 manganese Inorganic materials 0.000 claims description 8
- 239000011572 manganese Substances 0.000 claims description 8
- 235000019739 Dicalciumphosphate Nutrition 0.000 claims description 5
- 239000001506 calcium phosphate Substances 0.000 claims description 5
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 claims description 5
- 229940038472 dicalcium phosphate Drugs 0.000 claims description 5
- 229910000390 dicalcium phosphate Inorganic materials 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 5
- 235000010410 calcium alginate Nutrition 0.000 claims description 3
- 239000000648 calcium alginate Substances 0.000 claims description 3
- 229960002681 calcium alginate Drugs 0.000 claims description 3
- OKHHGHGGPDJQHR-YMOPUZKJSA-L calcium;(2s,3s,4s,5s,6r)-6-[(2r,3s,4r,5s,6r)-2-carboxy-6-[(2r,3s,4r,5s,6r)-2-carboxylato-4,5,6-trihydroxyoxan-3-yl]oxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylate Chemical compound [Ca+2].O[C@@H]1[C@H](O)[C@H](O)O[C@@H](C([O-])=O)[C@H]1O[C@H]1[C@@H](O)[C@@H](O)[C@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@H](O2)C([O-])=O)O)[C@H](C(O)=O)O1 OKHHGHGGPDJQHR-YMOPUZKJSA-L 0.000 claims description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 4
- 239000004471 Glycine Substances 0.000 claims 2
- IFJWCHSJEZRVMN-MDTVQASCSA-L calcium;(2s)-2,6-diaminohexanoate Chemical compound [Ca+2].NCCCC[C@H](N)C([O-])=O.NCCCC[C@H](N)C([O-])=O IFJWCHSJEZRVMN-MDTVQASCSA-L 0.000 claims 2
- 241000432824 Asparagus densiflorus Species 0.000 claims 1
- OPSXJNAGCGVGOG-DKWTVANSSA-L Calcium L-aspartate Chemical compound [Ca+2].[O-]C(=O)[C@@H](N)CC([O-])=O OPSXJNAGCGVGOG-DKWTVANSSA-L 0.000 claims 1
- HLBIGQDEEVNODU-RGMNGODLSA-N [Ca].C(CC)N[C@@H](CCO)C(=O)O Chemical compound [Ca].C(CC)N[C@@H](CCO)C(=O)O HLBIGQDEEVNODU-RGMNGODLSA-N 0.000 claims 1
- 229940034055 calcium aspartate Drugs 0.000 claims 1
- 239000007910 chewable tablet Substances 0.000 claims 1
- 235000010603 pastilles Nutrition 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 235000001465 calcium Nutrition 0.000 description 115
- 210000000988 bone and bone Anatomy 0.000 description 26
- 235000013305 food Nutrition 0.000 description 23
- 238000010521 absorption reaction Methods 0.000 description 17
- DHMQDGOQFOQNFH-UHFFFAOYSA-M Aminoacetate Chemical compound NCC([O-])=O DHMQDGOQFOQNFH-UHFFFAOYSA-M 0.000 description 16
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 12
- 235000005911 diet Nutrition 0.000 description 12
- 238000007469 bone scintigraphy Methods 0.000 description 11
- 239000004475 Arginine Substances 0.000 description 10
- 235000009697 arginine Nutrition 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 9
- 230000037213 diet Effects 0.000 description 9
- 208000001132 Osteoporosis Diseases 0.000 description 8
- 235000018977 lysine Nutrition 0.000 description 8
- 235000016709 nutrition Nutrition 0.000 description 8
- 235000010443 alginic acid Nutrition 0.000 description 7
- 229920000615 alginic acid Polymers 0.000 description 7
- 230000035764 nutrition Effects 0.000 description 7
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 6
- 238000013459 approach Methods 0.000 description 6
- -1 calcium ion compound Chemical class 0.000 description 6
- 239000000470 constituent Substances 0.000 description 6
- 230000036541 health Effects 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 235000013336 milk Nutrition 0.000 description 6
- 239000008267 milk Substances 0.000 description 6
- 210000004080 milk Anatomy 0.000 description 6
- 206010065687 Bone loss Diseases 0.000 description 5
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 description 5
- 229940024606 amino acid Drugs 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 5
- 239000001354 calcium citrate Substances 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 235000012054 meals Nutrition 0.000 description 5
- 235000002949 phytic acid Nutrition 0.000 description 5
- 235000013337 tricalcium citrate Nutrition 0.000 description 5
- 206010000060 Abdominal distension Diseases 0.000 description 4
- 206010010774 Constipation Diseases 0.000 description 4
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 4
- 229940009098 aspartate Drugs 0.000 description 4
- 239000005018 casein Substances 0.000 description 4
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 4
- 235000021240 caseins Nutrition 0.000 description 4
- 210000001072 colon Anatomy 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 206010006956 Calcium deficiency Diseases 0.000 description 3
- 102000018997 Growth Hormone Human genes 0.000 description 3
- 108010051696 Growth Hormone Proteins 0.000 description 3
- 229930003316 Vitamin D Natural products 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 229910021529 ammonia Inorganic materials 0.000 description 3
- 235000013365 dairy product Nutrition 0.000 description 3
- 230000000378 dietary effect Effects 0.000 description 3
- 235000020776 essential amino acid Nutrition 0.000 description 3
- 239000003797 essential amino acid Substances 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 239000000122 growth hormone Substances 0.000 description 3
- 229920001542 oligosaccharide Polymers 0.000 description 3
- 150000002482 oligosaccharides Chemical class 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 235000013311 vegetables Nutrition 0.000 description 3
- 235000019166 vitamin D Nutrition 0.000 description 3
- 239000011710 vitamin D Substances 0.000 description 3
- 150000003710 vitamin D derivatives Chemical class 0.000 description 3
- 229940046008 vitamin d Drugs 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 208000010392 Bone Fractures Diseases 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- 108010001441 Phosphopeptides Proteins 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- IMQLKJBTEOYOSI-UHFFFAOYSA-N Phytic acid Natural products OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 235000018823 dietary intake Nutrition 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000005484 gravity Effects 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000009245 menopause Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 239000000467 phytic acid Substances 0.000 description 2
- 229940068041 phytic acid Drugs 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 108010048734 sclerotin Proteins 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- DWNBOPVKNPVNQG-LURJTMIESA-N (2s)-4-hydroxy-2-(propylamino)butanoic acid Chemical compound CCCN[C@H](C(O)=O)CCO DWNBOPVKNPVNQG-LURJTMIESA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 208000006386 Bone Resorption Diseases 0.000 description 1
- 235000012905 Brassica oleracea var viridis Nutrition 0.000 description 1
- 244000064816 Brassica oleracea var. acephala Species 0.000 description 1
- 208000004434 Calcinosis Diseases 0.000 description 1
- 102000005701 Calcium-Binding Proteins Human genes 0.000 description 1
- 108010045403 Calcium-Binding Proteins Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000036693 Color-vision disease Diseases 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010016948 Food interaction Diseases 0.000 description 1
- 201000008892 GM1 Gangliosidosis Diseases 0.000 description 1
- 206010017577 Gait disturbance Diseases 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- 206010025476 Malabsorption Diseases 0.000 description 1
- 208000004155 Malabsorption Syndromes Diseases 0.000 description 1
- 102000003939 Membrane transport proteins Human genes 0.000 description 1
- 108090000301 Membrane transport proteins Proteins 0.000 description 1
- 235000017879 Nasturtium officinale Nutrition 0.000 description 1
- 240000005407 Nasturtium officinale Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 244000300264 Spinacia oleracea Species 0.000 description 1
- 235000009337 Spinacia oleracea Nutrition 0.000 description 1
- CPGKMLVTFNUAHL-UHFFFAOYSA-N [Ca].[Ca] Chemical compound [Ca].[Ca] CPGKMLVTFNUAHL-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- 230000001458 anti-acid effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000010256 bone deposition Effects 0.000 description 1
- 230000008468 bone growth Effects 0.000 description 1
- 230000024279 bone resorption Effects 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 102000014823 calbindin Human genes 0.000 description 1
- 108060001061 calbindin Proteins 0.000 description 1
- 150000001669 calcium Chemical class 0.000 description 1
- 229940092124 calcium citrate malate Drugs 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- MPCMQXRREZMSPJ-UHFFFAOYSA-L calcium;2-hydroxybutanedioate;2-hydroxypropane-1,2,3-tricarboxylic acid;pentahydrate Chemical compound O.O.O.O.O.[Ca+2].[O-]C(=O)C(O)CC([O-])=O.OC(=O)CC(O)(C(O)=O)CC(O)=O MPCMQXRREZMSPJ-UHFFFAOYSA-L 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 201000007254 color blindness Diseases 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000009547 dual-energy X-ray absorptiometry Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 235000004626 essential fatty acids Nutrition 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 206010016766 flatulence Diseases 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 230000030136 gastric emptying Effects 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 235000011868 grain product Nutrition 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000002650 habitual effect Effects 0.000 description 1
- WPEXVRDUEAJUGY-UHFFFAOYSA-B hexacalcium;(2,3,4,5,6-pentaphosphonatooxycyclohexyl) phosphate Chemical compound [Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])(=O)OC1C(OP([O-])([O-])=O)C(OP([O-])([O-])=O)C(OP([O-])([O-])=O)C(OP([O-])([O-])=O)C1OP([O-])([O-])=O WPEXVRDUEAJUGY-UHFFFAOYSA-B 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Substances N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 230000010189 intracellular transport Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- JCQLYHFGKNRPGE-FCVZTGTOSA-N lactulose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 JCQLYHFGKNRPGE-FCVZTGTOSA-N 0.000 description 1
- 229960000511 lactulose Drugs 0.000 description 1
- PFCRQPBOOFTZGQ-UHFFFAOYSA-N lactulose keto form Natural products OCC(=O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O PFCRQPBOOFTZGQ-UHFFFAOYSA-N 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000004220 muscle function Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 239000002417 nutraceutical Substances 0.000 description 1
- 235000021436 nutraceutical agent Nutrition 0.000 description 1
- 229940100691 oral capsule Drugs 0.000 description 1
- 235000021542 oral nutrition Nutrition 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 235000016046 other dairy product Nutrition 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 235000011962 puddings Nutrition 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 235000021391 short chain fatty acids Nutrition 0.000 description 1
- 150000004666 short chain fatty acids Chemical class 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- WPLOVIFNBMNBPD-ATHMIXSHSA-N subtilin Chemical compound CC1SCC(NC2=O)C(=O)NC(CC(N)=O)C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(C(C)CC)C(=O)NC(=C)C(=O)NC(CCCCN)C(O)=O)CSC(C)C2NC(=O)C(CC(C)C)NC(=O)C1NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C1NC(=O)C(=C/C)/NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C2NC(=O)CNC(=O)C3CCCN3C(=O)C(NC(=O)C3NC(=O)C(CC(C)C)NC(=O)C(=C)NC(=O)C(CCC(O)=O)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(N)CC=4C5=CC=CC=C5NC=4)CSC3)C(C)SC2)C(C)C)C(C)SC1)CC1=CC=CC=C1 WPLOVIFNBMNBPD-ATHMIXSHSA-N 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Substances C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
- A23L33/155—Vitamins A or D
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/10—Carbonates; Bicarbonates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/32—Manganese; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/34—Copper; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/42—Phosphorus; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/168—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Botany (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明公开了一种用于增强钙吸收的营养组合物。本发明的营养组合物将钙与特定剂量的L‑精氨酸和L‑赖氨酸结合。本发明的营养组合物还可包括特定的铜、锌、维他命D3。本发明还公开了一种通过上述营养组合物增强钙吸收的方法。
Description
技术领域
本发明涉及一种钙补充剂,尤其涉及一种与传统营养组合物相比能增强钙吸收的口服营养组合物及应用方法。
背景技术
钙,是人体中富含的无机物,能在很多食物中发现,并能可以作为一种可食用的物质添加到其他物体中及现有的一些药物中,如抗酸剂。血管收缩及舒张、肌肉功能、神经传导、细胞内信号转导及激素分泌都需要钙,尽管用来维持这些关键的新陈代谢所需的钙低于全部含量的1%。血清中的钙非常的稳定,不随饮食摄入量的变化而波动;人体从作为钙容器及钙来源的骨组织中吸收并利用钙,以维持血液、肌肉和细胞间液体中的钙的浓度的恒定。
人体剩余的99%的钙储存于骨骼及牙齿中,以支持骨骼及牙齿的结构及功能。骨骼本身一直在持续的重塑,随着钙的不断吸收和沉积到新的骨骼中。而当人体从骨组织中摄取钙来进行关键代谢功能时就会发生再吸收,当人体吸收新的钙并以骨组织的形式存在时就会发生沉积。骨吸收和沉积的平衡随年龄的变化而改变。生长期的儿童和青少年的骨形成超过吸收,而早期和中期的成年人的这两个过程大致相等。在老年人中,尤其是绝经后的妇女,骨骼的破坏超过形成,导致骨质流失,从而随着时间的推移,骨质疏松的风险会增加。给人体提供足够的钙摄入量是至关重要的,以便于人体能够最大限度地发挥骨骼的再吸收和沉积,为生命的各个阶段提供充足的钙储备,防止人生后期出现骨密度的问题。
补充剂中的钙主要以碳酸钙和柠檬酸钙两种形式存在。其中,碳酸钙更容易获得,同时也更加便宜和方便。由于碳酸钙的吸收依赖于胃酸,因此与食物一起摄入时吸收率最高。而柠檬酸钙是否与食物一起摄入其吸收效果相同。柠檬酸钙同样适用于色盲、炎症型肠病患者及吸收障碍患者。补充剂或强化食品中还以其他钙形式存在,包括葡萄糖酸盐、乳酸盐及磷酸盐。发现于一些强化果汁中的果酸钙是一种吸收良好的钙形式。
钙补充剂包括各种数量的钙元素。例如,碳酸钙中钙的比重为40%,而柠檬酸钙中钙的比重为21%。钙的吸收率取决于一次性摄入的钙元素的总量,吸收率随着总量的增加而降低。摄入量≤500mg时吸收率最高。例如,一个人每天从补充剂中摄入1000mg钙,由此他可以在一天内分两次分别摄入500mg。此外,吸收率还取决于各形式钙的生物利用度、溶解度,以及在消化过程中吸收时的可用度。
一些服用钙补充剂的人还可能会出现肠胃副作用,包括胀气、腹胀或便秘等一些症状。在消化过程中,由于碳酸钙不用于水,其相较于柠檬酸钙更易引起副作用,因此钙补充剂中的钙的形式也有必要考虑。而缓解上述症状的方式包括在一天中分散摄入钙或者随餐服用钙补充剂。
膳食钙的摄入的重要性日益得到认识,钙不仅对骨骼健康有益,而且还对预防高血压和结肠癌有着重要意义。在一些工业化国家中,钙的摄入不仅经常不足而且还在下降,主要是因为牛奶盒其他奶制品的消耗在下降。与此同时,骨质疏松症的患病率也在上升,骨质疏松症的特征是骨量减少(BMD)及骨组织微结构恶化,随之而来的是骨折风险的增加(Barclay,2011)。
在骨骼生长和成熟期间,也就是在人类20岁左右,人的骨骼中平均每天大概积累150mg的钙,直到达到骨量的峰值。在成熟期,身体(骨骼)大致处于钙平衡状态。男性从50岁开始,女性从更年期开始,骨骼平衡被打破,骨质从各处的骨骼中流失。而由于在绝经期早期骨质流失更快并低于骨量峰值,因此女性骨折的风险要高于男性。
因此,为人类找到达到高峰值骨量的解决方案对公众健康具有重要意义。其保持骨量峰值并将随年龄增长的骨质流失风险降低,对已经达到的骨量峰值的人来说同样具有重要意义,尤其是绝经后的女性。
从饮食中摄取足量的钙对于达到最佳骨量峰值及减少因衰老导致的骨质流失至关重要(Flynn&Cashman,1999)。牛奶及奶制品对于西方国家大多数人来说是最重要的膳食钙源,相较来说,谷类产品、水果及蔬菜的贡献要小得多。在其他乳制品较少的国家来说,日常饮食摄入的钙并非膳食钙的充足来源。此外,只有一小部分的钙随食物被吸收并被人体用于代谢。这就是食品中钙的生物利用度。
食品中的钙以盐的形式存在,或者与其他膳食成分配合以钙离子复合物的形式存在。钙被吸收之前必须以可溶的离子形式释放。因此钙的组成及其形成可溶性离子的能力对生物利用度及钙的吸收率至关重要的。钙在肠道中通过两种途径吸收——胞内途径和胞外途径。胞内途径通过黏膜转运蛋白及钙结合蛋白运输钙,为饱和的,可受生理和营养调控,通过维他命D调节。胞外途径通过黏膜细胞间的间隙连接运输钙,为不饱和的,本质上独立于生理和营养调控,依赖于浓度。人体对钙的吸收主要在小肠,但是一些证据也表明钙是一种结肠成分。
健康的成年人平均从混合饮食中吸收10%-30%的钙。肠道中钙的吸收效率受多种因素的影响。衰老、绝经和维他命D缺乏将降低健康人群对钙的吸收率。而维他命D过量、钙磷缺乏及妊娠与哺乳将提高钙的吸收率。
钙的吸收率还受到一些饮食因素的影响,包括习惯性钙摄入、食物中钙的含量、随食物或不随食物的钙摄入、钙的化学组成以及食物和饮食中存在的促进剂和抑制剂与肠胃的相互作用。
为了提高对食品中钙的吸收,人们对食品中钙的促进剂和抑制剂进行大量研究。其中,藻酸盐及植酸盐为两种公认的食品中钙吸收的抑制剂。因此,富含藻酸盐的蔬菜(如菠菜)的钙生物利用度较低,而藻酸盐含量低的蔬菜(如羽衣甘蓝和西洋菜)对钙的吸收较高。钙不被吸收是因为藻酸钙的溶解度极低,导致其在肠道中无法被利用。同样,来自高植酸大豆对钙的吸收也低于低植酸大豆。植酸盐抑制钙吸收归结于它在肠道中与钙形成强结合力的复合物。
一些食品成分被认为是钙吸收的潜在促进剂,如不易消化的低聚糖及个别牛奶成分,例如乳糖及酪蛋白磷酸肽。动物研究表明,在饮食中添加不易消化低聚糖可增加钙的吸收。这些低聚糖对人体的消化酶具有很强的抗性,当完整的到达结肠后被结肠微生物群发酵。产生的短链脂肪酸可降低结肠的pH,溶解不溶的钙复合物,使结肠中钙被利用。虽然几项研究表明了在体内的促进作用,但也指出,在中等剂量的条件下只有对钙有高需求的试验者如青少年和绝经后的妇女才能看到显著的效果。已被证实在体内能提高钙吸收的低聚糖包括果糖(FOS)、半乳糖(GOS)及乳果糖。
牛奶及奶制品中的钙能被人体很好的吸收,是由于乳糖和酪蛋白磷酸肽对钙吸收的促进作用。动物研究已表明,乳糖对钙的吸收和保留有促进作用。对于婴孩来说,含有乳糖的奶粉更利于钙的吸收。但对于成年人来说,乳糖只对β-半乳糖苷酶缺乏者的钙吸收有影响,而对健康的成年人并没有作用。酪蛋白磷酸化胜肽(CCP)通过蛋白酶作用于牛奶酪蛋白而在体内产生或者工业化产生。酪蛋白磷酸化胜肽已经证实其具有钙结合能力,并且在中性及碱性溶液中能保存钙。动物研究表明,CCP可提高钙的生物利用度,并阻止老龄动物的骨质流失。对人的研究则有些出入。CCP改善了对标准餐的钙吸收,而对低植酸和高植酸面包餐中的钙吸收并无影响。同样地,CCP能提高成年人从大米粥中吸收钙的量,但是对全谷类食品并未发现有这种效果。由此可表明,食物基质对钙的吸收起着重要作用,CCP仅对含中低含量抑制剂(如植酸盐)的食物有作用。
同样地,从理论上来说,脂肪也能被当作是一种促进剂,因为脂肪能减缓胃排空。然而,在一项对中年妇女的研究中,通过多元回归方法,并未发现脂肪的摄入对钙吸收影响。
尽管很多科学团队做了很多的工作研究,但并未提出令人满意的方案来解决缺钙的问题,而且,只有少部分原料被用来提高食品中钙的生物利用度。因此,有必要提供一种有助于增强钙吸收的营养组合物。
发明内容
同时给予钙和特定数量的必需氨基酸L-精氨酸(Arg)和L-赖氨酸(Lys)能显著提高钙的吸收。因此,本发明涉及L-精氨酸和L-赖氨酸的结合,以及包含所述L-精氨酸和L-赖氨酸的结合的营养产品。另一方面,本发明涉及一种具有增强钙吸收能力的食品产品。
精氨酸是一种α-氨基酸,它在1886年第一次被分离。L-精氨酸是20种最常见的天然氨基酸之一。精氨酸是一种条件性非必需氨基酸,例如,它可由人体产生,但是生物合成途径不能提供正常人体机能所需的全部的精氨酸的量,因此超出的量必需通过饮食补充。营养不良或者身体状况不佳的人通常体内无法合成的足够的精氨酸,因此建议增加含精氨酸食物的摄入。精氨酸存在于各种各样的食物中,包括动物和植物。精氨酸被报道过在生长激素的分泌中起作用,特别是在休息状态的试验者口服精氨酸能提高生长激素水平。然而,并不是所有的研究懂证实了这些发现。
赖氨酸是着一中能用于蛋白质合成的α-氨基酸,它含有α-氨基基团(在生物条件下为质子化的-NH3 +形态)、α-羧酸基团(在生物条件下为脱质子的-COO-形态)以及侧链赖氨酰基基团((CH2)4NH2),将其分类为一种带电的(生理pH)脂肪族的氨基酸。它对人体至关重要,这就意味着人体无法合成它且必须从饮食中获取。
精氨酸和赖氨酸参与骨骼的代谢和生长。实际上,精氨酸不仅参与与胶原合成有关的基底(聚胺及L-脯氨酸)的合成,还参与生长激素(GH)、类胰岛素一号增长因子(IGF-I)及一氧化氮(NO)[1-3]的生成。赖氨酸与促进钙吸收、肾保护及骨胶原交联过程有关[4,5]。根据本发明公开的内容,精氨酸及赖氨酸与钙按特定比例结合产生一种营养组合物,通过提高生物利用度来增加钙的吸收。
在本发明一实施方式中,一种以帮助钙吸收来改善骨密度的营养组合物,每100g中,含21g~36g的钙及至少15g的L-精氨酸与L-赖氨酸,其中,L-精氨酸及L-赖氨酸以2:1的比例存在。
在本发明另一实施方式中,一种以帮助钙吸收来改善骨密度的营养组合物,每100g中,含21g~36g的钙,425mg~770mg的锌,53mg~92mg的铜,107mg~183mg的锰及260mcg~550mcg的维他命D3,及至少15g的L-精氨酸与L-赖氨酸,其中,L-精氨酸及L-赖氨酸以2:1的比例存在。
本发明的其他特征及有益效果将在下述具体实施方式中进行描述及体现。
具体实施方式
可以理解的,基于本发明中的实施例,任何熟悉本技术领域的技术人员在本发明披露的技术范围内,可轻易想到的变化或者替换所获得的所有其他实施例,都属于本发明保护的范围。
根据一方面,本发明提供一种粉状的营养组合物,其每100g粉体中包含:21~36g的钙,425~770mg的锌,53~92mg的铜,107~183mg的锰及260~550mcg的维他命D3。另外,所述营养组合物包括30mg的精氨酸和15mg的赖氨酸。
下表1中揭露了本发明的营养组合物所具有的特征。
表1
下表2中对由一粒1400mg的口服的胶囊构成的本发明的营养组合物进行说明。
表2
1400.000mg
钙的总量 | 400mg |
锌的总量 | 8mg |
铜的总量 | 1mg |
锰的总量 | 2mg |
维他命D3的总量 | 200IU |
本发明的营养组合物还可提供最小限度的、部分的或者全部的营养支持。在一较佳实施方式中,所述营养组合物与食物或者其他营养组合物搭配服用。在一些实施方式中,所述营养组合物可在被食用前与食物或者其他营养组合物混合在一起,或者在食用食物或者其他营养组合物之前或之后服用。
所述营养组合物可以是营养完备的,也可以是非完备的。本领域技术人员将认识到,营养是否完备取决于很多因素,包括但不仅限于使用所述营养组合物的试验者的年龄、临床状况及饮食摄入量。一般而言,营养完备意味着本发明的营养组合物提供正常人所需的足够的碳水化合物、脂类、必需脂肪酸、蛋白质、必需氨基酸、条件性必需氨基酸、维他命、矿物质及能量。对于营养物质,“必需”一词是指人体合成的任何营养物质,其数量不足以维持正常生长和健康,因此必须由饮食提供,而“条件性必需”一词是指营养物质必须在人体无法获得足够量的用于进行内源性合成的前驱体化合物的条件下由饮食提供。所述营养组合物可为现有的任何形态,包括粉体、悬浮液、糊状物、布丁、固体、液体、浓缩液、即用型产品。在某一特定的实施方式中,所述营养组合物为一粉体。
本发明的营养组合物提高钙的生物利用度可由以下内容证明。
为了确定效果,几百个试验者服用本发明的营养组合物。下面实施例结果用来进一步描述本发明,但是本发明的范围并不仅限于具体实施例中的营养组合物。所述实施例的试验者的年龄范围为50岁到75岁。下面的实施例结果中,所述试验者按照本发明所述营养组合物规定的剂量服用。
骨密度测试结果通过T值反应。T值表示的是你的骨密度比一个30岁的健康成年人的骨密度高多少或者低多少。医疗服务人员用最低的T值来诊断骨质疏松症。双能X线骨密度测量法(DEXA)用来测定骨骼的状态,并用T值表示。
根据世界卫生组织(WHO)的数据,T值为-1.0或者以上为正常骨密度,例如0.9,0及-0.9。T值在-1.0到-2.5之间则表示骨密度低或者骨质疏松,例如-1.1,-1.6及-2.4。骨质疏松症的诊断为T值为-2.5或者以下,例如-2.6,-3.3及-3.9。一个人的T值越低,则骨密度越低。-1.0的T值低于0.5的T值,-3.5的T值低于-3.0的T值。
实施例1
一位65岁的男性试验者被诊断为骨质疏松症,在诊断时服用了市面上出售的钙营养组合物。初次骨骼扫描显示所述试验者的T值为-2.4。在服用了六个月的传统的市面上出售的钙营养组合物后,T值显示其骨密度的改善状况甚微。
随后,所述试验者每天2粒的服用本发明的营养组合物。每个胶囊包含1.4g的所述营养组合物。特别的,每个胶囊包含(以元素表示):2.36mg钙(天冬氨酸盐)、32.34mg钙(磷酸二钙)、333.96mg钙(碳酸钙)、29.49mg钙(甘氨酸盐)、0.949mg钙(藻酸盐)、0.901mg钙(赖氨酸盐)、8mg锌(甘氨酸盐)、1mg铜(甘氨酸盐)、2mg锰(甘氨酸盐)、200IU维他命D3(胆骨化醇)、30mg L-精氨酸基底、15mg L-赖氨酸(HCL)、15.000mg硬脂酸镁及33.925mg大米浓缩蛋白。每个胶囊中钙元素的总量为400mg。六个月后,进行骨骼扫描,T值已经提高至-1.9。一年后,再次进行骨骼扫描,T值已经提高至-1.1。并未出现腹胀、便秘等副作用。
实施例2
一位54岁的女性试验者被诊断为缺钙。初次骨骼扫描显示所述试验者的T值为-1.3。而后所述试验者开始本发明的营养组合物,每日随餐服用2粒胶囊。特别的,每个胶囊包含(以元素表示):1.73mg钙(天冬氨酸盐)、23.77mg钙(磷酸二钙)、245.46mg钙(碳酸钙)、21.68mg钙(甘氨酸盐)、0.698mg钙(藻酸盐)、0.662mg钙(赖氨酸盐)、5.95mg锌(甘氨酸盐)、0.74mg铜(甘氨酸盐)、1.5mg锰(甘氨酸盐)、146IU维他命D3(胆骨化醇)、30mg L-精氨酸基底、15mg L-赖氨酸(HCL)。每个胶囊中钙元素的总量为294mg。六个月后,进行骨骼扫描,她的T值已经提高至-0.8。并未出现腹胀、便秘等副作用。
实施例3
一位75岁的女性试验者在绊跌仆倒时伤到了胸椎。她被诊断为骨质疏松症,并且骨骼扫描显示她的T值为-2.5。此外,在此期间她偶尔会胸痛和腰痛。
在她接受创伤治疗的同时服用本发明的营养组合物。每天在吃饭时服用2粒胶囊。每个胶囊为1.8g。特别的,每个胶囊包含(以元素表示):2.97mg钙(天冬氨酸盐)、40.75mg钙(磷酸二钙)、420.79mg钙(碳酸钙)、37.16mg钙(甘氨酸盐)、1.20mg钙(藻酸盐)、1.14mg钙(赖氨酸盐)、10.78mg锌(甘氨酸盐)、1.28mg铜(甘氨酸盐)、2.56mg锰(甘氨酸盐)、272IU维他命D3(胆骨化醇)、34mg L-精氨酸基底、17mg L-赖氨酸(HCL)。每个胶囊中钙元素的总量为504mg。在此期间,所述试验者还服用其他药物。六个月后,进行骨骼扫描,显示她的T值已经提高至-2.2。此外,所述试验者的疼痛发生率也降低了。一年后,骨骼扫描的T值为-1.7。
实施例4
一位70岁的男性试验者被诊断为缺钙。初次骨骼扫描显示所述试验者的T值为-1.8。然后他开始服用本发明的营养组合物,每天随餐服用2粒胶囊。特别的,每个胶囊包含(以元素表示):2.07mg钙(天冬氨酸盐)、28.30mg钙(磷酸二钙)、292.22mg钙(碳酸钙)、25.80mg钙(甘氨酸盐)、0.83mg钙(藻酸盐)、0.79mg钙(赖氨酸盐)、6.98mg锌(甘氨酸盐)、0.87mg铜(甘氨酸盐)、1.75mg锰(甘氨酸盐)、254IU维他命D3(胆骨化醇)、30mg L-精氨酸基底、15mg L-赖氨酸(HCL)。每个胶囊中钙元素的总量为350mg。六个月后,进行骨骼扫描,显示T值为-1.3。一年后,骨骼扫描显示T值为-1。并未出现腹胀、便秘等副作用。
这些实施例结果支持了本发明的营养组合物显著增加钙吸收及该少骨骼密度的结论。因此,本发明的独特组合相较于典型的钙营养组合物改善了吸收。
上述实施例为本发明较佳的实施方式,但本发明的实施方式并不受上述实施例的限制,以上实施方式仅是用于解释权利要求书。然本发明的保护范围并不局限于说明书。任何熟悉本技术领域的技术人员在本发明披露的技术范围内,可轻易想到的变化或者替换,都包含在本发明的保护范围之内。
Claims (11)
1.一种以增强钙吸收来改善骨密度的营养组合物,每100g的营养组合物中,包括:
21g~36g的钙;
425mg~770mg的锌;
53mg~92mg的铜;
107mg~183mg的锰;
260mcg~550mcg的维他命D3;以及
至少15g的L-精氨酸及L-赖氨酸;
其中,L-精氨酸及L-赖氨酸以2:1的比例存在。
2.如权利要求1所述的营养组合物,其特征在于,所述21g~36g的钙包括碳酸钙。
3.如权利要求1所述的营养组合物,其特征在于,所述21g~36g的钙包括天冬氨酸钙。
4.如权利要求1所述的营养组合物,其特征在于,所述21g~36g的钙包括磷酸二钙。
5.如权利要求1所述的营养组合物,其特征在于,所述21g~36g的钙包括甘氨酸钙。
6.如权利要求1所述的营养组合物,其特征在于,所述21g~36g的钙包括藻酸钙。
7.如权利要求1所述的营养组合物,其特征在于,所述21g~36g的钙包括赖氨酸钙。
8.如权利要求1所述的营养组合物,其特征在于,所述21g~36g的钙选自碳酸钙、天冬氨酸钙、磷酸二钙、甘氨酸钙、藻酸钙及赖氨酸钙中的至少两种。
9.如权利要求1所述的营养组合物,其特征在于,所述营养组合物为一种口服形态,选自片剂、胶囊、锭剂、咀嚼片及松散粉粒。
10.一种以增强钙吸收来改善骨密度的营养组合物,每100g的营养组合物中,包括:
21g~36g的钙;以及
至少15g的L-精氨酸及L-赖氨酸;
其中,L-精氨酸及L-赖氨酸以2:1的比例存在。
11.一种通过一营养组合物增强钙吸收的方法,所述方法包括:
提供每100g中含21g~36g的钙的所述营养组合物;以及
提供每100g中含至少15g的L-精氨酸及L-赖氨酸的所述营养组合物;
其中,L-精氨酸及L-赖氨酸以2:1的比例存在。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/838,603 US20190175533A1 (en) | 2017-12-12 | 2017-12-12 | Nutritional supplement for improved calcium absorption |
US15/838603 | 2017-12-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN109938354A true CN109938354A (zh) | 2019-06-28 |
Family
ID=66734864
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201811513099.XA Pending CN109938354A (zh) | 2017-12-12 | 2018-12-11 | 一种用于增强钙吸收的营养组合物及其应用方法 |
Country Status (2)
Country | Link |
---|---|
US (2) | US20190175533A1 (zh) |
CN (1) | CN109938354A (zh) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005023020A1 (en) * | 2003-09-05 | 2005-03-17 | Matthias Rath | Composition and method for facilitating bone healing |
CN101268836A (zh) * | 2007-03-23 | 2008-09-24 | 天津天狮生物工程有限公司 | 一种营养高钙冲剂及其生产制作工艺 |
CN101690591A (zh) * | 2009-10-08 | 2010-04-07 | 苟春虎 | 牦牛骨髓多肽长骨增高片(粉) |
CN101692907A (zh) * | 2009-09-15 | 2010-04-14 | 苟春虎 | 高活性牦牛骨髓生物钙复方胶囊 |
CN105777534A (zh) * | 2014-12-24 | 2016-07-20 | 辽宁科硕营养科技有限公司 | 柠檬酸钙盐及其制备方法与用途 |
CN106036387A (zh) * | 2016-05-31 | 2016-10-26 | 苟春虎 | 超级藜麦儿童生长营养包 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69332777D1 (de) * | 1992-09-23 | 2003-04-24 | Kv Pharm Co | Multivitamin- und mineralstoffergänzung für schwangere |
-
2017
- 2017-12-12 US US15/838,603 patent/US20190175533A1/en not_active Abandoned
-
2018
- 2018-12-11 CN CN201811513099.XA patent/CN109938354A/zh active Pending
-
2019
- 2019-11-13 US US16/682,171 patent/US20200113860A1/en not_active Abandoned
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005023020A1 (en) * | 2003-09-05 | 2005-03-17 | Matthias Rath | Composition and method for facilitating bone healing |
CN1845683A (zh) * | 2003-09-05 | 2006-10-11 | 马赛厄斯·拉思 | 用于促进骨愈合的组合物和方法 |
CN101268836A (zh) * | 2007-03-23 | 2008-09-24 | 天津天狮生物工程有限公司 | 一种营养高钙冲剂及其生产制作工艺 |
CN101692907A (zh) * | 2009-09-15 | 2010-04-14 | 苟春虎 | 高活性牦牛骨髓生物钙复方胶囊 |
CN101690591A (zh) * | 2009-10-08 | 2010-04-07 | 苟春虎 | 牦牛骨髓多肽长骨增高片(粉) |
CN105777534A (zh) * | 2014-12-24 | 2016-07-20 | 辽宁科硕营养科技有限公司 | 柠檬酸钙盐及其制备方法与用途 |
CN106036387A (zh) * | 2016-05-31 | 2016-10-26 | 苟春虎 | 超级藜麦儿童生长营养包 |
Also Published As
Publication number | Publication date |
---|---|
US20190175533A1 (en) | 2019-06-13 |
US20200113860A1 (en) | 2020-04-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3708115B2 (ja) | 混合カルシウム及びビタミンd補給品 | |
JP3251287B2 (ja) | カルシウム及び微量ミネラル補給品 | |
US8703209B2 (en) | Composition and method for modulating hydrogen ion physiology | |
US6667063B2 (en) | Nutritional or therapeutic supplement and method | |
US5232709A (en) | Calcium and trace mineral supplements comprising estrogen | |
CZ24999A3 (cs) | Farmaceutický prostředek | |
JPH07252156A (ja) | 骨粗鬆症予防治療材 | |
EA016259B1 (ru) | Применение кальций-пептидного компонента для снижения веса тела | |
JP2920434B2 (ja) | カルシウム及び食物繊維含有飲食物とその製造方法 | |
CN109938354A (zh) | 一种用于增强钙吸收的营养组合物及其应用方法 | |
CN1016756B (zh) | 制取果汁牛奶的方法 | |
EP1214894B1 (en) | Food formulations with a high calcium content | |
CN110463988A (zh) | 一种低脂低渗型全营养配方粉及其制备方法 | |
JP2964290B2 (ja) | ミネラル吸収促進剤 | |
JP3033245B2 (ja) | オリゴペプチド組成物及びオリゴペプチド含有食品 | |
JPH11243914A (ja) | カルシウム吸収促進飲食物 | |
JPH05262655A (ja) | カルシウムの腸管吸収促進剤および腸管吸収性を高め たカルシウム組成物ならびにそれを含有するカルシウ ム飲料 | |
JP2001120226A (ja) | 骨強化剤及び骨強化用食品組成物 | |
JP2020195284A (ja) | 廃用性筋委縮予防・改善組成物 | |
TW201825011A (zh) | 蛋白質效率提升用之組成物 | |
Singh et al. | Zinc, Calcium, Fluoride, and Selenium Fortification | |
Diaz-Curiel et al. | Nutrition and bone health: Its relationship to osteoporosis | |
Rogula et al. | Laparoscopic Roux-en-Y gastric bypass: Postoperative management and nutritional evaluation | |
CN1121784A (zh) | 蛋黄素 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190628 |